|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nu-Med Plus, Inc. (NUMD), a medical device company which investigates and develops applications of Nitric Oxide technologies in the medical field, has selected Millennium Biosciences as their strategic partner for company quality and regulatory service. Mr. Mike D’Amico who leads Millennium has been a successful, focused, quality-driven scientific leader with global strategic Quality systems and Regulatory experience within the scientific community. Inhaled Nitric oxide(INO) is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems and may have future applications for a variety of other diseases and medical complications that are currently being investigated.
Nu-Med Plus, Inc. (NUMD), a medical device company which explores and develops medical applications of new technologies in the medical field, announced its patent filing for its pioneering chemically reactive coating. The coating ensures that only a contaminant free nitric oxide, a life saving drug for neonates, reaches the patient. Nu-Med Plus has developed a distinctive method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing.
Nu-Med Plus, Inc. , a medical device company which explores and develops medical applications of new technologies in the medical field, announced its notification of patent approval for its low cost Nitric ...